TriSalus Life Sciences

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Swarmer (SWMR) moves into combat drone hardware with Vataga IP deal as revenue scale remains unproven

Octant’s OCT-980 gains FDA orphan status, but can an oral molecule slow inherited vision loss?

Hitachi Digital unites GlobalLogic and Hitachi Digital Services, but can 35,000 specialists accelerate AI revenue growth?

EU eyes major Australian critical minerals investment as trade deal could remove 5.5% tariff

Infographic showing TriSalus Life Sciences receiving FDA 510(k) clearance for TriNav Advance, highlighting expanded access to smaller and more distal blood vessels, a planned limited market release, and key financial figures including Q2 2026 revenue of $11.4 million and 2025 revenue of $45.2 million.

TriSalus gets TriNav Advance FDA clearance after delay weighed on 2026 guidance

TriSalus Life Sciences has received FDA 510(k) clearance for TriNav Advance, enabling Pressure-Enabled Drug Delivery through smaller distal vessels and removing a regulatory delay that had already contributed to a reduction in the company’s 2026 revenue outlook.

byVenkatesh

September 28, 2026

TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases

TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting…

byPallavi Madhiraju

November 5, 2023

The Latest

Swarmer (SWMR) moves into combat drone hardware with Vataga IP deal as revenue scale remains unproven

Octant’s OCT-980 gains FDA orphan status, but can an oral molecule slow inherited vision loss?

Hitachi Digital unites GlobalLogic and Hitachi Digital Services, but can 35,000 specialists accelerate AI revenue growth?

EU eyes major Australian critical minerals investment as trade deal could remove 5.5% tariff

TriSalus gets TriNav Advance FDA clearance after delay weighed on 2026 guidance

TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases

Swarmer (SWMR) moves into combat drone hardware with Vataga IP deal as revenue scale remains unproven

Octant’s OCT-980 gains FDA orphan status, but can an oral molecule slow inherited vision loss?

Hitachi Digital unites GlobalLogic and Hitachi Digital Services, but can 35,000 specialists accelerate AI revenue growth?

EU eyes major Australian critical minerals investment as trade deal could remove 5.5% tariff

Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings

France plans to replace Parcoursup by 2028 after student protests force education reforms

HSBC profit rises 32% to $9.6bn, but legal comparisons complicate the recovery story

UK seeks Made in Europe exemption as EU industrial rules threaten British carmakers